A phase Ib trial of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with early-stage resectable hepatocellular carcinoma
Release date:
2024-01-23
Description:
Neoadjuvant therapy of ICIs plus stereotactic body radiotherapy (SBRT) has shown promising results in several types of solid tumours but not HCC. This is a phase Ib clinical trial of neoadjuvant SBRT plus PD-1 (tislelizumab) in HCC patients (pts). Prior to resection, pts receive 8 Gy x 3 fractions of SBRT together with 2 cycles of PD-1 with an interval of 3 weeks. HCC resection is scheduled 4 weeks after the second dose of PD-1, followed by adjuvant PD-1 for up to 1 year. We plan to enrol 20 participants in this trial.
For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.
DAC of Shandong Cancer HospitalIs is a data management organization, relying on Shandong first Medical University, mainly responsible for data management, analysis, treatment and control of this study.
You need to install the Aspera Connect plugin before uploading your files. If you dont have Aspera Connect plugin installed in your computer, please Download Aspera Connectand install it first.
[path/to/ascp]: Microsoft Windows: C:\Program Files\Aspera\Aspera Connect\bin\ascp.exe or
c:\users\[username]\AppData\Local\Programs\Aspera\Aspera Connect\bin\ascp.exe
Mac OS X: /Applications/Aspera/Connect.app/Contents/Resources/ascp (for admin's installation) or
/Users/[username]/Applications/Aspera/Connect.app/Contents/Resources/ascp (for non-admin's installation)
Linux: /opt/aspera/bin/ascp or
/home/[username]/aspera/connect/bin/ascp
[path/to/key/file] must be an absolute path, e.g.: /home/keys/aspera.openssh
[path/to/folder/containing/files] needs to specify the local folder that contains all the files to upload.
HRA006511.xlsx